Literature DB >> 13491339

Use of relaxin in the treatment of scleroderma.

G G CASTEN, R J BOUCEK.   

Abstract

Entities:  

Keywords:  RELAXIN/therapeutic use; SCLERODERMA/therapy

Mesh：

Substances：

Year:  1958        PMID： 13491339     DOI： 10.1001/jama.1958.02990040005002

Source DB:  PubMed          Journal:  J Am Med Assoc        ISSN： 0002-9955


× No keyword cloud information.
  16 in total

1.  Failure of relaxin inthe treatment of scleroderma.

Authors:  J E JEFFERIS; A S DIXON
Journal:  Ann Rheum Dis       Date:  1962-09       Impact factor: 19.103

2.  Term labour: its facilitation by relaxin; a preliminary report.

Authors:  R X SANDS; J H KO
Journal:  Can Med Assoc J       Date:  1959-06-01       Impact factor: 8.262

3.  Relaxin; a clinical review.

Authors:  R X SANDS
Journal:  Can Med Assoc J       Date:  1958-06-15       Impact factor: 8.262

Review 4.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

Review 5.  Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Authors:  Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce
Journal:  Mol Cell Endocrinol       Date:  2019-02-14       Impact factor: 4.102

Review 6.  Serelaxin in clinical development: past, present and future.

Authors:  Elaine Unemori
Journal:  Br J Pharmacol       Date:  2017-01-29       Impact factor: 8.739

Review 7.  Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.

Authors:  Sandeep Yadav; Jun Liu; Thomas M Scherer; Yatin Gokarn; Barthélemy Demeule; Sonoko Kanai; James D Andya; Steven J Shire
Journal:  Biophys Rev       Date:  2013-03-14

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Surgical resections in parous patients with distal ileal and colonic Crohn's disease.

Authors:  C U Nwokolo; W C Tan; H A Andrews; R N Allan
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

Review 10.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.